McDonald's is developing higher-protein menu options to cater to a growing number of customers using popular GLP-1 weight-loss medications such as Ozempic and Wegovy.
CEO Chris Kempczinski announced during the company's Wednesday earnings call that the fast-food giant is testing menu items designed to appeal to people taking GLP-1 drugs, which suppress appetite and alter eating habits.
"As adoption grows, we know that consumers' behavior changes," Kempczinski said. He noted these customers tend to favor protein-rich meals and consume fewer calories overall.
Vice President Jill McDonald highlighted existing high-protein options already available, including Snack Wraps, Sausage Biscuit sandwiches, and McCrispy Strips. The company is also monitoring changes in snacking habits and beverage preferences among GLP-1 users, who tend to avoid sugary drinks.
The chain confirmed it has longer-term plans to serve this customer segment but did not provide specific details about new menu items or rollout timelines.
GLP-1 medications like Ozempic and Wegovy have gained widespread adoption across the United States. An EY consumer products expert estimated last year that approximately 10 percent of the U.S. population uses some form of GLP-1 drugs. The recent approval and availability of pill forms of these medications is expected to drive even greater adoption.
The drugs are reshaping the food and beverage industry as users adjust portion sizes and food preferences. McDonald's is not alone in adapting to this shift. Shake Shack introduced a "Good Fit Menu" in December featuring high-protein and lettuce-wrapped burger options. Food brands including Conagra Brands and General Mills now offer smaller portions labeled "GLP-1 friendly."
Despite the industry changes, Kempczinski said McDonald's has not yet seen evidence of GLP-1 drugs having a material impact on the company's business. The chain reported strong fourth-quarter results, with revenue of $6.83 billion and earnings per share of $3.05, beating analyst expectations.